SNWV (53) TELA (36) MDAI (21) XTNT (69) ⌘ Pro Terminal →

Sensus Healthcare Inc. (SRTS) — RQD Stock Rating Cockpit

$2.77 -1.77% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Sensus Healthcare Inc. (SRTS) carries a Roarable Rating of D (Sell) with 46/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $45.6M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRTS)Realized 20D OHLCV Swing Band: ±10.2%

RSI-14 MOMENTUMNEUTRAL RANGE

39.330 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

6.50>3.0 Fortress Safe

PIOTROSKI F-SCORESOLID CORE (5–6)

5 / 99-Pt Accounting

52-WEEK LASER RANGE4% OF RANGE

L: $3$2.77H: $5

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (43% profit margin), though cash flow growth is moderate rather than explosive right now.

Factor Grade: CRQD 13 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 11 / 40

3. Hidden Risks & Market Weather● WATCH

SEC fine-print scan & interest-rate fit

No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.

Factor Grade: D+RQD 22 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on SRTS

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (65)

-31.3% ROIC with 43.2% gross margin and 0.73% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (70)

Altman-Z 6.50 and Piotroski 5/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (32)

11/40 institutional & smart-money positioning score with 8/20 macro alignment.

Bull Case: Why Buyers Like SRTS

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRTS)

✓Walkthrough of SRTS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRTS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -30.23%🛡️ HOLDING TREND SUPPORT

2026-10-30O $2.75H $2.90L $2.75C $2.77VOL 27.8K

RES: $4.32SUP: $2.67SMA50: $3.04SMA200: $3.54

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRTS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRTS Butterfly Map → + Track SRTS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -34.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on SRTS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRTS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRTS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRTS)

Health Care Rank #459 of 1016 ⚔️ SNWV vs SRTS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRTS vs. SNWV, TELA, MDAI, XTNT)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Sensus Healthcare Inc. (SRTS) ranks #459 by composite RQD confidence (46/100, grade D) and #763 by equity capitalization ($45.6M). Within this direct 5-issuer industry benchmark cohort, SNWV leads on earnings valuation at 3.8x trailing P/E, while SNWV leads on capital efficiency and profitability with 67.3% ROIC and 77.1% gross margin. XTNT currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with SRTS at 46/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRTS ACTIVE Sensus Healthcare Inc.	D	46/100	—	43.2%	-31.3%	-1.77%	$45.6M	Benchmark Subject
SNWV SANUWAVE Health Inc.	D+	53/100	3.8x	77.1%	67.3%	0.00%	$45.3M	/snwv-vs-srts →
TELA TELA Bio Inc.	D-	36/100	—	67.7%	-35.0%	-5.74%	$41.5M	/tela-vs-srts →
MDAI Spectral AI Inc. (Class A)	E	21/100	—	45.4%	-35.0%	+0.64%	$50.5M	/mdai-vs-srts →
XTNT Xtant Medical Holdings Inc.	C+	69/100	—	62.9%	12.8%	+1.54%	$40.7M	/xtnt-vs-srts →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001494891

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sensus Healthcare Inc. (SRTS) reported GAAP revenue of $27.5M (-34.3% vs. FY2024 revenue of $41.8M , and +12.6% cumulative change since FY2023) , GAAP net income of -$7.7M, operating cash flow of $528.0K, and free cash flow of $332.0K (+130.0% YoY). On the balance sheet, SRTS closed FY2025 with $53.0M in total assets against $0 in total debt (Altman Z-Score: 6.50, Piotroski F-Score: 5/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$27.5M	-$7.7M	$528.0K	$332.0K	$53.0M	—
FY2024 (FY)	2024-12-31	$41.8M	$6.6M	-$831.0K	-$1.1M	$62.2M	—
FY2023 (FY)	2023-12-31	$24.4M	$485.0K	-$2.1M	-$2.1M	—	—

3. SRTS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRTS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Sensus Healthcare Inc. (NASDAQ: SRTS) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 46/100 at a spot price of $2.77 (-1.77% 1D, market cap $45.6M). Pillar breakdown: Fundamental Cash Engine 13/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 14/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, SRTS ranks #459 in composite RQD confidence.

How does SRTS compare to SNWV and TELA in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), SRTS carries a Roarable D (46/100 RQD), trailing P/E of N/A, gross margin of 43.2%, and ROIC of -31.3%. By comparison, SNWV (SANUWAVE Health Inc.) holds a D+ grade (53/100 RQD, P/E 3.8x, ROIC 67.3%, cap $45.3M) and TELA (TELA Bio Inc.) posts a D- grade (36/100 RQD, P/E N/A, ROIC -35.0%, cap $41.5M). Among the 5-stock peer group, SNWV leads on earnings multiple (3.8x) while SNWV leads on capital efficiency (67.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for SRTS?

Per SRTS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001494891), Sensus Healthcare Inc. generated $27.5M in revenue (-34.3% YoY), -$7.7M in net income, and $332.0K in free cash flow against $53.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is SRTS trading relative to its 50-day, 200-day, and 52-week technical levels?

SRTS last traded at $2.77 (-1.77% on volume of 17,639 shares), positioning the stock -8.88% below its 50-day simple moving average ($3.04) and -21.75% below its 200-day simple moving average ($3.54). Across its 52-week range of $2.66 to $5.49, SRTS sits at the 3.9% percentile with a 14-day RSI of 39.3 (NEUTRAL RANGE) and an implied next-earnings move of ±10.2% ($2.49 to $3.05).

SRTS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell SRTS stock right now?

Sensus Healthcare Inc. (SRTS) currently earns a Roarable Rating of D (Sell — SELL) with 46/100 RQD Confidence. Stretched risk/reward at current multiples (-31% return on capital) under elevated 10-year interest-rate pressure.

What is SRTS's 12-month price target and RQD AI Jury consensus?

SRTS's 12-month base price target is $2.62 (range $2.04 to $5.76), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: SRTS RQD Cockpit SRTS 12M Forecast SRTS Earnings & Move SRTS Dividends & DRIP SRTS Insiders & 13F SRTS Whale Options SRTS Profit Sankey SRTS News & Why